CoChat

Monoclonal antibodies capable of discriminating the human inhibitory Fcγ‐receptor IIB (CD32B) from the activating Fcγ‐receptor IIA (CD32A): biochemical, biological and functional characterization

Open access
Veri, Maria‐Concetta, Gorlatov, Sergey, Li, Hua, Burke, Steve, Johnson, Syd, Stavenhagen, Jeffrey, Stein, Kathryn E., Bonvini, Ezio, Koenig, Scott · 2007 · Immunology
Cited by 157

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Summary: Human CD32B (FcγRIIB), the low‐affinity inhibitory Fcγ receptor (FcγR), is highly homologous in its extracellular domain to CD32A (FcγRIIA), an activating FcγR. Available monoclonal antibodies (mAb) against the extracellular region of CD32B recognize both receptors. Through immunization of mice transgenic for human CD32A, we generated a set of antibodies specific for the extracellular region of CD32B with no cross‐reactivity with CD32A, as determined by enzyme‐linked immunosorbent assay and surface plasmon resonance with recombinant CD32A and CD32B, and by fluorescence‐activated cell sorting analysis of CD32 transfectants. A high‐affinity mAb, 2B6, was used to explore the expression of CD32B by human peripheral blood leucocytes. While all B lymphocytes expressed CD32B, only a fraction of monocytes and almost no polymorphonuclear cells stained with 2B6. Likewise, natural killer cells, which express CD32C, a third CD32 variant, did not react with 2B6. Immune complexes co‐engage the inhibitory receptor with activating Fcγ receptors, a mechanism that limits cell responses. 2B6 competed for immune complex binding to CD32B as a monomeric Fab, suggesting that it directly recognizes the Fc‐binding region of the receptor. Furthermore, when co‐ligated with an activating receptor, 2B6 triggered CD32B‐mediated inhibitory signalling, resulting in diminished release of inflammatory mediators by FcεRI in an in vitro allergy model or decreased proliferation of human B cells induced by B‐cell receptor stimulation. These antibodies form the basis for the development of investigational tools and therapeutics with multiple potential applications, ranging from adjuvants in FcγR‐mediated responses to the treatment of allergy and autoimmunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2567.2007.02588.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 157

Metadata

Authors
Veri, M., Gorlatov, S., Li, H., Burke, S., Johnson, S., Stavenhagen, J., Stein, K. E., Bonvini, E., & Koenig, S.
Venue
Immunology
Publisher
Wiley
Published
2007-03-26
Volume
121
Issue
3
Pages
392-404
ISSN
  • 0019-2805 (ISSN-L)
  • 1365-2567
OpenAlex
W2052746029
Cited by
157
References
2
FWCI
6.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monoclonal antibodies capable of discriminating the human inhibitory Fcγ‐receptor IIB (CD32B) from the activating Fcγ‐receptor IIA (CD32A): biochemical, biological and functional characterization. https://app.cochat.ai/papers/10.1111/j.1365-2567.2007.02588.x
The paper
Veri, M., Gorlatov, S., Li, H., Burke, S., Johnson, S., Stavenhagen, J., Stein, K. E., Bonvini, E., & Koenig, S. (2007). Monoclonal antibodies capable of discriminating the human inhibitory Fcγ‐receptor IIB (CD32B) from the activating Fcγ‐receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology. https://doi.org/10.1111/j.1365-2567.2007.02588.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.